Arab Press

بالشعب و للشعب
Friday, Mar 29, 2024

AstraZeneca's vaccine rollout nets $275m in sales - but drags on its profits

AstraZeneca's vaccine rollout nets $275m in sales - but drags on its profits

The FTSE 100 drugs is actually being financially hurt by the pandemic despite its key role in trying to defeat the virus.

Today's quarterly results from AstraZeneca are a very timely reminder that, for all the debate about the drug-maker's involvement in the Oxford COVID vaccine, it is of very little importance to the financial fortunes of what is currently the fifth-largest company in the FTSE 100.

In fact, AZ is actually losing money on its involvement in the vaccine rollout.

AZ today reported sales for the first three months of the year of $7.3bn - up some 15% on the same period last year.

The vaccine is being sold at cost


To put that into context, $275m of that came from sales of the COVID vaccine AZ devised with the University of Oxford, representing a mere 4% of the total.

Moreover, because AZ is selling the vaccine at cost, the product actually turned out to be a drag on the company's earnings.

These came in at $1.63 per share, up 55% on the same period last year, way ahead of the $1.48 that analysts had been expecting.

AZ said today the figure would have been $1.66 were it not for the cost of producing the Oxford vaccine.

Given that, one could be forgiven for asking whether AZ regrets its involvement in the vaccine rollout, particularly given the criticism it has received in some countries and the legal battle with the European Commission in which the company now finds itself.

Pascal Soriot, AZ's chief executive, insisted today that was absolutely not the case.

AstraZeneca has found itself in a legal battle with the EU over the vaccine

He told reporters: "We actually got involved because we wanted to help and we thought we could make a difference and develop this vaccine.

"We never pretended that we were going to be perfect, and certainly, we've learned a few things along the way.

"But imagine if we had not stepped up.

"A year ago people were talking about there being 120, 130 different vaccines.

"Where are all those vaccines? They are nowhere.

"We never overpromised, we communicated what we thought we would achieve at the time based on the capacity that we had put together.

"We don't regret anything because we look forward, not backward.

"We did our very best to help the world, and overall the team should be very proud of the difference we've made and lives we've saved.

Chief executive Pascal Soriot said: "We are proud of what we have done"


"We are proud of what we have done, and only disappointed we could not do even more."

The disclosure is nonetheless significant because it is the first time that AZ, which with its manufacturing partners has so far supplied 300 million doses of the vaccine around the world, has actually disclosed its sales to date from the Oxford vaccine.

And, happily, it does not appear to have distracted investors too much from what was nonetheless a strong set of results and which at one point sent shares of AZ up by more than 4%.

This is a company which, a decade ago, looked like a sitting duck.

Sales from its blockbuster drugs were falling as they came off patent and attempts to deliver new blockbusters had misfired.

Sure enough, an unwanted bid from US giant Pfizer materialised in early 2014.

Mr Soriot and his colleagues fought off that approach partly by promising that investors were better off waiting for AZ to bring to market the new products in its pipeline.

Today's results prove again how AZ is delivering on that promise and especially in the key therapy area of oncology.

Sales were up 20% across the piece, with revenues for Tagrisso, the lung cancer treatment, rising by 17% to $1.2bn and sales of Lynparza, a treatment for ovarian cancer, up by 37% to $543m in the quarter.

Imfinzi, a treatment for lung and bladder cancer, saw its sales rise during the quarter by 20% to $556m.

The picture was no less encouraging in other therapy areas.

Farxiga, AZ's diabetes treatment, saw quarterly sales rise by 54% to $625m while sales of Fasenra, an asthma treatment, were up by 31% to $260m.

Elsewhere, there was little news on Alexion, the rare disease specialist specialist that AZ agreed to buy in December last year for $39bn.

The City was initially lukewarm on the deal but, gradually, shareholders appear to have come around to the idea.

AZ reiterated today that the deal is due to close between July and September this year.

There were one or two blemishes.

AstraZeneca fought off an unwanted approach from Pfizer in 2014


Sales of Brilinta, AZ's heart attack drug, were down by 8% during the quarter to $374m, reflecting fewer acute coronary syndrome hospital admissions, hitting demand in China in particular.

Similarly, sales of Pulmicort, another asthma treatment, fell by 13% to $330m as COVID-19 impacted the hospital treatment of respiratory patients and cheap generic versions of the drug appeared in some markets.

Those setbacks highlight the extent to which the pandemic has actually hurt AZ.

It has hit demand for some of AZ's other products by preventing patients with conditions other than COVID getting the hospital treatment they need.

And that is even before taking into account the fact that not only has producing the COVID vaccine hit its earnings, it has dragged AZ into unwanted legal rows, which will surely have been a drain on management time.

Mr Soriot could be forgiven for reflecting on the old adage that "no good deed goes unpunished".

Newsletter

Related Articles

Arab Press
0:00
0:00
Close
China Criticizes US for Vetoing UN Ceasefire Resolution in Gaza
Saudi Arabia ranks first in UN index for e-government services in MENA
Israel Records 20% Drop In GDP, War In Gaza Is The Reason
Saudi Arabia's FDI Inflows Grow with New International Standards
Venture Capitals Power Up Across MENA Region
PM Modi Announces Opening Of New CBSE Office In Dubai
January Funding for MENA Startups Totals $86.5 Million
Saudi Arabia accelerates digital economy growth through Nvidia partnership
Israel unveils tunnels underneath Gaza City headquarters of UN agency for Palestinian refugees
Israel deploys new military AI in Gaza war
Egypt threatens to suspend key peace treaty if Israel pushes into Gaza border town, officials say
Saudi Arabia Warns Of A "Humanitarian Catastrophe" If Israel Moves On Rafah
US University To Shut Qatar Campus Due To "Heightened Mideast Instability"
Facebook and Instagram Ban Iran's Supreme Leader
Defense Technology Showcase Held in Riyadh
Saudi Arabia’s non-oil exports rise 2.5% to $6bn in November 2023: GASTAT
Rolls-Royce Executive Encourages Saudi Women to Tap into Their Inner 'Superhero' for Success in Defense Industry
Saudi Arabia launches National Academy of Vehicles and Cars
Saudi Tourism Minister Reveals Plan for 250,000 New Hotel Rooms by 2030
SAR to more than double eastern network passenger capacity with new trains deal
Saudi Arabia Enhances National Defense with New Partnerships
Saudi Aramco Maintains Arab Light Crude Pricing to Asia for March
NEOM Establishes New York Office to Support Investors
Saudi Wealth Fund Draws in Over $25 Billion Worth of Investments in Three Years, Al-Rumayyan Reveals
The Saudi Kingdom's Ultimatum to Israel: A Win-Win Peace with Saudi Arabia and the Arab World, or a Lose-Lose Continued Occupation and Endless Conflict
Biden condemns anti-Arab hate after WSJ opinion piece calls Dearborn ‘jihad capital’
Turkey Releases Seven Hostages Captured by Pro-Gaza Gunman
Arab Parliament Commends Women's Contributions to Societal Development
British and Hungarian Foreign Ministers visited Lebanese leaders to stress the importance of enacting UN Resolution 1701
Yemen's Houthis Say They Targeted British Merchant Vessel In Red Sea
Donald Trump Nominated for Nobel Peace Prize for 'Historic' Middle East Policy
US lawmakers approve F-16 jet sale to Turkey following NATO expansion support
Saudi Arabia Climbs 25 Places in World Bank's National Statistics Indicator
Tourism Growth in Saudi Arabia Fuels Advancements in the Hospitality Industry," Says Rotana Official
Houthi Rebels Request Departure of UN Staff from Yemen, Including US and UK Personnel, within a Month
Modi Inaugurates Hindu Temple on Site of Demolished Mosque in India
Over 25,000 Deaths in Gaza Amid Israeli Offensive
Escalating Clashes in Gaza as Israel Distributes Leaflets to Assist in Locating Hostages
Turkey's First Astronaut Set to Launch for International Space Station Today
Head of Palestinian Investment Fund Warns More People May Die of Hunger Than War in Gaza
Palestinian Envoy Criticizes UK for Alleged 'Double Standards' in Policies Toward Israel
Morocco to Lead UN Human Rights Council in 2024
Is artificial intelligence the solution to cyber security threats?
Egypt has been identified as the leading military force among Arab nations and ranks 15th globally
The AI Revolution in the Workforce: CEOs at Davos Predict Major Job Cuts in 2024
Iranian Nobel Laureate Narges Mohammadi Receives Additional Prison Sentence
"Gazans Urge Israeli Forces to Target Hamas in Leaked Audio"
Biden States US and UK Airstrikes on Houthis Were a 'Defensive Action
Large Pro-Palestine Rally in London as Gaza Conflict Hits Day 100
South Africa Urges World Court to Halt Israeli Actions in Gaza
×